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Lithium: from mood stabilizer to 
putative cognitive enhancer
The monovalent cation lithium, whose introduction in psychia-
try dates back at the end of the 1940s, remains the first-line agent 
in the management of patients with bipolar disorder (BD). It is 
effective in the treatment of moderate-to-severe acute mania, 
prophylactic for recurrent manic and depressive episodes, and re-
duces the risk of suicide. It can also boost antidepressants effects 
in the treatment of major depressive disorder (Albert et al., 2014). 
More recently, a growing body of evidence seems to suggest that 
the benefits of lithium extend beyond mood stabilization. In vi-
tro, lithium has been shown to provide neuroprotection against 
excitotoxicity induced by glutamate and N-methyl-D-aspartate 
(NMDA) receptor activation, calcium, thapsigargin, β-amyloid, 
aging, serum/growth factor deprivation, low potassium con-
centration, C2-ceramide, aluminum, ouabain, and specific HIV 
regulatory proteins. Lithium’s neuroprotective effects have fur-
ther been demonstrated in a series of in vivo animal models of 
ischemic/hemorrhagic stroke, traumatic brain/spinal cord injury 
(TBI/SCI), Huntington’s disease (HD), Alzheimer’s disease (AD), 
amyotrophic lateral sclerosis (ALS), fragile X syndrome (FXS), 
Parkinson’s disease (PD), retinal degeneration, multiple sclerosis 
(MS), alcohol-induced degeneration, Down syndrome, spinoc-
erebellar ataxia-1, HIV-associated neurotoxicity, and irradiation 
(Chiu et al., 2013). In spite of this, very little is understood about 
its mechanism of action. Recent research findings indicate that 
lithium’s neuroprotective effects may stem, at least in part, from 
its ability to inhibit the glycogen synthase kinase-3β (GSK-3β) 
by directly binding to its enzyme’s magnesium-sensitive site and 
indirectly by enhancing phosphorylation of this kinase at spe-
cific serine residues. Indeed lithium’s direct inhibition of GSK-
3β leads to activation of several transcription factors, including 
cyclic adenosine monophosphate (cAMP) response element 
binding protein (CREB), heat-shock factor-1 (HSF-1), and 
β-catenin, with subsequent induction of major neurotrophic, 
angiogenic, anti-inflammatory, and anti-apoptotic factors such 
as brain-derived neurotrophic factor (BDNF), nerve growth fac-
tor (NGF), glial cell line-derived neurotrophic factor (GDNF), 
vascular endothelial growth factor (VEGF), heat shock protein 
70 (HSP70), and B-cell lymphoma/leukemia-2 protein (Bcl-
2), respectively. Suppressed GSK-3β further reduces the activity 
of the pro-apoptotic proteins p53 and Bax and their negative 
regulatory action on Bcl-2. Noteworthy, BDNF and NGF have 
been reported to function as both downstream molecules re-
sulting from the inhibition of GSK-3β and upstream signals able 
to inhibit this molecular pathway via specific survival signaling 
cascades such as the phosphatidylinositol-3-kinase (PI3K)/Akt 
and the MAP kinase (MEK)/ERK pathways. Lithium also indi-
rectly inhibits GSK-3β via PI3K-dependent activation of protein 
kinase C (PKC), cAMP-dependent activation of protein kinase A 
(PKA), and the Wnt/β-catenin pathway (via Frizzled receptors). 
On the other hand, by decreasing inositol 1,4,5-trisphosphate 
(IP3) levels, lithium has been shown to induce autophagy, a sort 
of ‘quality control’ process believed to be particularly important 
in neurodegenerative disorders such as HD, AD, ALS, and PD 
characterized by the accumulation of misfolded disease-causing 
proteins. In these same neurodegenerative disorders as well as 
in stroke, TBI/SCI, retinal degeneration, MS, and HIV, lithium 
inhibits glutamate-induced excitotoxicity mediated by NMDA 
receptors, specifically attenuating the NR2B subunit constitutive 
tyrosine phosphorylation, and subsequent calcium influx, thus 
suppressing excitotoxicity-induced p38 and c-Jun N-terminal 
kinase (JNK), and subsequent transcription factor activator pro-
tein-1 (AP-1) activation to block neuronal apoptosis. Inhibition 
of oxidative stress, implicated in numerous central nervous sys-
tem (CNS) disorders such as BD, stroke, TBI/SCI, HD, AD, and 
ALS may further underlie lithium beneficial effects towards these 
pathologies (Chiu et al., 2013, Figure 1). 
In contrast to preclinical studies, clinically based evidence 
of lithium neuroprotective effects are still limited and typically 
restricted to patients with BD. The most replicated finding from 
structural neuroimaging studies is an association between long-
term lithium treatment and increased gray matter volume in 
brain areas implicated in emotional processing and cognitive 
control such as the anterior cingulate, ventral prefrontal cortex, 
paralimbic association cortex, superior temporal gyri, amygda-
la, and hippocampus, which suggests that lithium has consid-
erable neuroprotective and/or neurotrophic effects (Chiu et al., 
2013). Noteworthy, in the study by Benedetti et al. (2015), long-
term lithium treatment and the less active GSK-3β rs334558*G 
gene promoter variant were found to be synergistically associ-
ated with increased frontal lobe gray matter volumes in patients 
with BD. N-acetyl-aspartate, a putative marker for neuronal 
viability and function, was also reported to be increased in the 
brain of patients with BD after lithium treatment (Hajek et al., 
2012). With regard to the effects of lithium on cognition, data 
are at present somewhat ambiguous. Conclusions from a recent 
meta-analysis point overall towards various cognitive deficits 
in psychiatric patients, as well as in normal volunteers treated 
with lithium, across the areas of immediate verbal learning 
and memory, creativity, and psychomotor speed (Wingo et al., 
2009). However, there is also evidence for better/improved ex-
ecutive functions and memory, mostly related to the activity of 
prefrontal cortex and medial temporal lobe respectively, in lithi-
um treated BD patients (Rybakowski et al., 2009). 
In our cross-sectional study (Bersani et al., 2016), results 
obtained seem to confirm a potential medial temporal lobe 
neuroprotective effects of lithium in patients with BD. Subjects 
enrolled were 15 euthymic BD patients undergoing long-term 
clinical maintenance treatment with lithium (for at least 12 
months), 15 matched patients treated with other mood-stabiliz-
ing drugs and who had never received lithium, and 15 matched 
healthy subjects. Cognitive functions were assessed using the 
Cambridge Neuropsychological Test Automated Battery(CAN-
TAB) tests of visual memory [Paired Associates Learning (PAL); 
Delayed Matching to Sample (DMS)], executive functions [Spa-
tial Span (SSP); Spatial Working Memory (SWM); and Stocking 
of Cambridge (SOC)], attention [Rapid Visual Information 
Processing (RVIP) and  Intra/Extradimensional set shift (IED)], 
decision making [Information Sampling Task (IST)] and re-
sponse inhibition [Stop Signal Task (SST)]. Taken together, 
BD patients demonstrated robust deficits in the visual episodic 
memory PAL and executive functions SSP, SWM, and SOC tests. 
Once subdivided in treatment subgroups, only non-lithium 
treated BD patients demonstrated impairments in the visual 
episodic memory PAL test. Covarying for lifetime antipsychotic 
medication did not change the outcome. Noteworthy, successful 
performance on the PAL test is dependent on functional integrity 
of the medial temporal lobe. Evidence from lesion studies in rats, 
monkeys, and humans, as well as functional imaging studies in 
normal human volunteers, suggest that medial temporal lobe 
structures, such as the hippocampus, parahippocampal gyrus 
and enthorinal cortex are implicated in the main cognitive com-
ponent of this test. Across a number of studies, the PAL test has 
also been shown to be particularly effective (sensitivity = 100%; 
specificity = 92%) in differentiating early AD from healthy older 
adults and it is now one of the most widely used test in assessing 
the integrity of the hippocampal memory formation (Junkkila et 
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al., 2012). In line with our findings, suggestions have been ad-
vanced that, in patients with BD, a continued lithium treatment 
may exert a preventing action against the onset of dementia 
(Nunes et al., 2007). Always in this context, a following study 
by Nunes et al. (2013) has demonstrated how a microdose lith-
ium treatment (300 μg per day) administered for a period of 15 
months may be able to prevent cognitive loss in patients with 
AD. Indeed, lithium treatment has been shown to present dis-
ease-modifying effects in AD, mainly by the modification of its 
pathophysiology via inhibition of the overactive GSK-3, which 
definitely has been related to amyloid precursor protein pro-
cessing and tau hyperphosphorylation, and by the provision of 
neurotrophic and neuroprotective support. It is a fact that clini-
cal trials of lithium in AD and other neurodegenerative illnesses 
are now under way, unfortunately, up to date, with conflicting 
results. Methodological issues including small samples size, the 
use of diverse research designs and/or the lack of consistency in 
most of the neuropsychological tests administered could be at 
the base of such outcomes. With regard to prefrontal cortex and 
associated executive functions, even though a favorable effect 
of lithium has been suggested also for this cognitive domain, in 
our study, both BD treatment groups have showed moderately 
impaired working memory and strategy use. In the study by 
Rybakowski et al. (2009), better indexes of executive functions 
were showed in persons who benefited from long-term lithium 
therapy compared with lithium non-responders. In contrast, 
our lithium-treated BD patients did not seem to benefit of such 
a positive effect. Of note, subjects included in the aforemen-
tioned study were a group of patients with a mean of 15 years 
of lithium treatment, which certainly enables a more accurate 
assessment of lithium cognitive positive effect. Moreover, nei-
ther the research design nor the neuropsychological assessment 
is comparable between our study and that of these authors. 
With regard to attention and decision-making/response inhibi-
tion, an absence of a favorable effect of lithium was seen in our 
patients. At the same time, lithium did not seem to affect these 
two cognitive domains.
To the best of our knowledge, our study is the first to have 
demonstrated, by means of a highly sensitive test of visual 
memory, a potential hippocampus neuroprotective effect of 
lithium in patients with BD. Undoubtedly, other studies are 
needed to finally recognize lithium as a potential cognitive 
enhancer. Future studies should include, apart from highly 
sensitive cognitive tests, specific neurotrophic biomarkers, such 
as BDNF, NGF, etc. Finally, it will be of outmost importance 
to evaluate the minimal length of treatment and the optimum 
serum level in order to combine potential clinical benefit and, 
particularly for older patients, clinical safety.
Adele Quartini*, Angela Iannitelli, Giuseppe Bersani
Department of Medical-Surgical Sciences and Biotechnologies, Faculty 
of Pharmacy and Medicine - “Sapienza” University of Rome, DSM ASL/
LT - Unit of Psychiatry, “A. Fiorini” Hospital, Via Firenze - 04019 - 
Terracina (LT), Italy
*Correspondence to: Adele Quartini, M.D., edy.qua@fastwebnet.it.
Accepted: 2016-08-10
doi: 10.4103/1673-5374.189175         
How to cite this article: Quartini A, Iannitelli A, Bersani G (2016) 
Lithium: from mood stabilizer to putative cognitive enhancer. Neural 
Regen Res 11(8):1234-1235.                                              
                                         
References
Albert U, De Cori D, Blengino G, Bogetto F, Maina G (2014) Lithium treat-
ment and potential long-term side effects: a systematic review of the litera-
ture. Riv Psichiatr 49:12-21.
Benedetti F, Poletti S, Radaelli D, Locatelli C, Pirovano A, Lorenzi C, Vai B, 
Bollettini I, Falini A, Smeraldi E, Colombo C (2015)Lithium and GSK-3α 
promoter gene variants influence cortical gray matter volumes in bipolar 
disorder. Psychopharmacology (Berl) 232:1325-1336.
Bersani G, Quartini A, Zullo D, Iannitelli A (2016) Potential neuroprotective 
effect of lithium in bipolar patients evaluated by neuropsychological as-
sessment: preliminary results. Hum Psychopharmacol 31:19-28.
Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013) Therapeutic potential 
of mood stabilizers lithium and valproate acid: beyond bipolar disorder. 
Pharmacol Rev 65:105-142.
Hajek T, Bauer M, Pfenning A, Cullis J, Ploch J, O’Donovan C, Bohner G, 
Klingebiel R, Young LT, Macqueen GM, Alda M(2012) Large positive effect 
of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar 
disorder: 2-centre study. J Psychiatry Neurosci 37:185-192.
Junkkila J, Oja S, Laine M, Karrasch M (2012) Applicability of the CAN-
TAB-PAL computerized memory test in identifying amnestic mild cog-
nitive impairment and Alzheimer’s disease. Dement Geriatr Cogn Disord 
34:83-89.
Nunes MA, Viel TA, Buck HS (2013) Microdose lithium treatment stabilized 
cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer 
Res 10:104-107.
Nunes PV, Forlenza OV, Gattaz WF (2007) Lithium and risk for Alzheimer’s 
disease in elderly patients with bipolar disorder. Br J Psychiatry 190:359-
360.
Rybakowski JK, Permoda-Osip A, Borkowska A (2009) Response to prophy-
lactic lithium in bipolar disorder may be associated with a preservation of 
executive cognitive functions. Eur Neuropsychopharmacol 19:791-795.
Wingo AP, Wingo TS, Harvey PD, Baldessarini RJ (2009) Effects of lithium 
on cognitive performance: a meta-analysis. J Clin Psychiatry 70:1588-1597.
Figure 1 Overview of the proposed mechanisms underlining lithium 
neuroprotective effects.
Through the direct/indirect inhibition of glycogen synthase kinase-3β (GSK-
3β), lithium is hypothesized to disinhibit several transcription factors, includ-
ing cyclic adenosine monophosphate (cAMP) response element binding pro-
tein (CREB), heat-shock factor-1 (HSF-1), and β-catenin, with subsequent 
induction of major neurotrophic, angiogenic, anti-inflammatory, and an-
ti-apoptotic factors such as brain-derived neurotrophic factor (BDNF), nerve 
growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), 
vascular endothelial growth factor (VEGF), heat shock protein 70 (HSP70), 
and B-cell lymphoma/leukemia-2 protein (Bcl-2), respectively. Lithium also 
indirectly inhibits GSK-3β via PI3K-dependent activation of protein kinase C 
(PKC), cAMP-dependent activation of protein kinase A (PKA), and the Wnt/
β-catenin path way. The ability of lithium to decrease inositol 1,4,5-trisphos-
phate (IP3) levels has also been shown to induce autophagy. Furthermore, 
lithium inhibits glutamate-induced excitotoxicity mediated by NMDA recep-
tors and subsequent calcium influx, thus suppressing excitotoxicity-induced 
p38 and c-Jun N-terminal kinase (JNK), and subsequent transcription factor 
activator protein-1 (AP-1) activation to block neuronal apoptosis.
